Opiates are a class of drugs derived directly from the opium poppy plant, Papaver somniferum. The term specifically refers to natural compounds found in the plant’s resin, with morphine and codeine being the most well-known. “Opioids” is the broader umbrella term covering opiates along with their semi-synthetic and fully synthetic cousins like oxycodone, fentanyl, and methadone.1PubMed Central. Synthetic opioids: a review and clinical update In everyday conversation the words are often used interchangeably, but the distinction matters when discussing where these drugs come from and how they differ. Opiates sit at the root of a family tree that now includes dozens of prescription medications, street drugs, and medications used to treat addiction itself.
Where Opiates Come From
The opium poppy has been cultivated for thousands of years. When the seed pod of Papaver somniferum is scored, it oozes a milky latex that dries into raw opium. Inside that resin sits a cocktail of alkaloids, the most abundant and pharmacologically important being morphine, codeine, and thebaine. The plant builds these molecules through a biosynthetic chain that starts with the amino acid tyrosine and proceeds through a series of intermediate compounds before arriving at thebaine, then codeine, and finally morphine.2PubMed. Biosynthesis of the morphine alkaloids
Morphine was the first of these compounds to be chemically isolated, a feat accomplished by the German pharmacist Wilhelm Sertürner in the early 1800s.3PubMed. The Chemical History of Morphine: An 8000-year Journey, from Resin to de-novo Synthesis That isolation marked a turning point in medicine: for the first time, physicians could administer a precisely measured dose of a pure painkiller instead of guessing at the potency of crude opium. Codeine, morphine’s weaker relative, was isolated shortly afterward. Every semi-synthetic opioid developed since, from heroin (diacetylmorphine, first synthesized in the 1870s) to oxycodone, starts with one of these plant-derived alkaloids as its chemical backbone.
How Opiates Affect the Brain and Body
Your body already makes its own opioid-like chemicals, called endogenous opioids. These molecules help regulate pain signals, mood, and reward. The discovery of endogenous opioids reshaped the understanding of how addiction and reward circuitry work in the brain, showing that the same systems activated by morphine are involved in motivated behavior, social bonding, and responses to other drugs.4PubMed. Endogenous opioids and reward When you take an opiate like morphine or codeine, it plugs into the same receptors your endogenous opioids use, but with far greater intensity and duration.
There are several types of opioid receptors, but the mu-opioid receptor is the main target for pain relief and euphoria. When morphine binds to a mu receptor on a nerve cell, it triggers a cascade that quiets the cell’s activity: it reduces the cell’s internal signaling molecules, opens certain ion channels that make the cell less excitable, and closes others that would normally help it fire.5BJA Open. Opioids and opioid receptors; understanding pharmacological mechanisms as a key to therapeutic advances and mitigation of the misuse crisis The net result is that pain signals get dampened before they reach conscious awareness. But those same receptors also sit in brain regions responsible for breathing, gut motility, and emotional reward, which is why opiates affect so much more than just pain.
The euphoria that opiates can produce traces back to the brain’s dopamine system. Morphine activates dopamine-producing cells in a deep brain region called the ventral tegmental area, which sends signals to the nucleus accumbens, a hub for processing reward and motivation.6PubMed. Brain mechanisms of drug reward and euphoria This dopamine surge is what makes opiates feel good and is a major reason they carry addiction risk.
Medical Uses of Opiates
Pain management remains the primary medical application. Morphine is still one of the most effective analgesics available for moderate-to-severe pain, especially in surgical recovery, traumatic injuries, and cancer care. Codeine is prescribed for milder pain, though its effectiveness depends heavily on a person’s genetics, a point covered in more detail below. In controlled studies, morphine reliably reduced pain scores in both fast and slow metabolizers, while codeine only worked in people whose bodies could efficiently convert it to morphine.7PubMed. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects
Codeine has also been used for decades as a cough suppressant, working through the mu-opioid receptor in the central nervous system.8PubMed Central. Central and peripheral mechanisms of narcotic antitussives: codeine-sensitive and -resistant coughs Despite its long-standing reputation as the “gold standard” cough medicine, the evidence behind that reputation has eroded. Placebo-controlled trials have found codeine no more effective than a sugar pill at suppressing cough from upper respiratory infections or chronic obstructive pulmonary disease.9PubMed Central. Codeine and cough: an ineffective gold standard This is one of those areas where medical tradition has outrun the data.
A less widely known use is breathlessness. In palliative care, low-dose oral morphine is used to ease the distressing sensation of being unable to catch your breath, particularly in patients with advanced cancer or end-stage lung disease. There is strong evidence supporting daily low-dose sustained-release morphine for breathlessness in patients who are not already taking opioids, and at least one national therapeutics regulatory body has formally recognized this indication.10BMJ Supportive & Palliative Care. Opioids for breathlessness: a narrative review Opioids are considered a safe and effective frontline treatment for refractory breathlessness in palliative settings.11PubMed Central. Management of dyspnea in palliative care Oral or parenteral opioids are the mainstay of dyspnea management in this context, sometimes supplemented with other medications.12PubMed Central. Dyspnea review for the palliative care professional: treatment goals and therapeutic options
Common Side Effects
Even at prescribed doses, opiates produce a recognizable set of side effects that stem from mu-opioid receptors scattered throughout the body. These include nausea and vomiting, itching, sedation, and the characteristic pinpoint pupils known as miosis.13PubMed. Adverse effects of systemic opioid analgesics The pupil effect is so reliable that clinicians use pupil size as a gauge of opioid exposure. In ICU patients receiving fentanyl, pupil diameter shrank by an average of about one millimeter compared to when fentanyl was absent, and pupillary reflex speed also slowed.14PubMed Central. The Influence of Opioids on Pupil Initial Diameter and Pupillary Dilation Velocity in ICU Patients
Constipation deserves special mention because, unlike most other side effects, the gut does not get used to it over time. While your body develops tolerance to the sedating and euphoric effects of opiates fairly quickly, the gut’s opioid receptors resist adaptation. This means someone on long-term opiate therapy can expect constipation to persist for as long as they take the drug.15PubMed Central. Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities Opioid-induced constipation is one of the most common reasons patients want to stop or reduce their medication, and it has its own category of prescription treatments designed to block opioid receptors only in the gut without reversing pain relief in the brain.
Tolerance, Dependence, and Withdrawal
Tolerance means that the same dose produces a weaker effect over time, so you need more to get the same result. Dependence means your body has adapted to the drug’s presence and reacts badly when the drug is removed. These are related but distinct phenomena, and both can develop with regular opiate use even when someone is following their prescription exactly.
The traditional explanation for tolerance centers on the opioid receptors themselves becoming less responsive. With repeated exposure to morphine, the receptors undergo changes that make them slower to signal and slower to recover. This desensitization process involves multiple enzymes that chemically modify the receptor, and chronic use seems to recruit additional enzymes that weren’t involved in the initial response, making the problem compound over time.16Frontiers in Systems Neuroscience. Cellular Tolerance Induced by Chronic Opioids in the Central Nervous System More recent research has complicated this picture, suggesting that the way receptors are pulled inside the cell and recycled also plays a role, and that receptor internalization might actually reduce tolerance in some contexts rather than contribute to it.17PubMed. Opioid tolerance-in search of the holy grail The full story of tolerance is still being worked out.
Withdrawal is what happens when a person who is physically dependent suddenly stops taking opiates. The symptoms are intensely unpleasant: sweating, muscle aches, anxiety, insomnia, diarrhea, goosebumps, and a deep, restless agitation. One of the key drivers is a surge in the brain’s noradrenaline system. During opiate use, noradrenaline release is suppressed. When the drug disappears, that system rebounds hard, especially in a brainstem region called the locus coeruleus. The overactivity of this region accounts for many of the classic withdrawal symptoms.18Neuroscience & Biobehavioral Reviews. Participation of Noradrenergic Pathways in the Expression of Opiate Withdrawal: Biochemical and Pharmacological Evidence This is also why clonidine, a medication that dampens noradrenaline activity, has been used for decades to ease withdrawal symptoms.
Overdose and Respiratory Depression
The most dangerous acute risk of opiates is respiratory depression. Opioid receptors sit in the brainstem centers that control your automatic urge to breathe. At high enough doses, opiates can suppress that drive until breathing slows dangerously or stops. An overdose typically presents with both a low breathing rate and falling oxygen levels.19PubMed Central. Importance of the correct diagnosis of opioid-induced respiratory depression in adult cancer patients and titration of naloxone Pupil constriction is also characteristic of opiate overdose, though under extreme oxygen deprivation the pupils can dilate somewhat as the body’s stress response kicks in.20Anesthesiology. Pupillary Effects of High-dose Opioid Quantified with Infrared Pupillometry
Naloxone is the emergency antidote. It works by competing with the opiate for the mu-opioid receptor, physically displacing it.21PubMed Central. Clinical Pharmacokinetics and Pharmacodynamics of Naloxone The key detail many people don’t realize is that naloxone wears off faster than many opiates do, meaning a person can wake up from an overdose, seem fine, and then slip back into respiratory failure after the naloxone clears. Anyone who has been revived with naloxone needs medical monitoring. In clinical settings, the recommended approach when opioid-induced respiratory depression is confirmed is to first try rousing the patient and reducing the opioid dose, turning to naloxone only when necessary, titrated in small increments to restore breathing without triggering full-blown withdrawal.19PubMed Central. Importance of the correct diagnosis of opioid-induced respiratory depression in adult cancer patients and titration of naloxone
Why Your Genetics Change the Effects
Codeine is actually a prodrug: it does very little on its own until your liver converts it into morphine. That conversion depends almost entirely on a single liver enzyme, CYP2D6.22PubMed. The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects The gene encoding CYP2D6 is one of the most variable in the human genome, and where you fall on the spectrum has real consequences.
People with extra copies of the gene are called ultra-rapid metabolizers. They convert codeine into morphine faster and in larger amounts than expected, which can lead to toxicity even at standard doses. A case report in the New England Journal of Medicine documented life-threatening opioid intoxication in a patient with three or more functional copies of the CYP2D6 gene who had been taking codeine at a normal dose, compounded by other medications that affected the clearance pathway.23PubMed. Codeine intoxication associated with ultrarapid CYP2D6 metabolism At the opposite end are poor metabolizers, who barely convert codeine at all and get little to no pain relief from it.24The Pharmacogenomics Journal. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication
The prevalence of these genetic variants differs across populations. In some East Asian populations, a reduced-function allele called CYP2D6*10 is the most common variant, leading to lower morphine production from codeine.22PubMed. The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects In parts of North Africa and the Middle East, ultra-rapid metabolizer rates are higher. This kind of variation is one reason a standard codeine prescription can be dangerously strong for one patient and completely useless for another. Pharmacogenomic testing, which identifies your CYP2D6 status before you fill a prescription, is increasingly available but still far from routine.
Long-Term Effects on the Immune System and Hormones
Beyond tolerance, dependence, and addiction, chronic opiate use produces subtler changes that often go unrecognized. Opioid receptors are not limited to the brain; they also sit on immune cells. Long-term opiate therapy has been associated with measurable shifts in immune function, including lower levels of natural killer cells and altered inflammatory signaling.25PubMed. The effects of long-term opioid treatment on the immune system in chronic non-cancer pain patients: A systematic review In cancer patients, the evidence suggests that some opioids may be immunosuppressive and could be associated with higher infection rates and possibly reduced survival, though disentangling the drug’s effect from the underlying disease is difficult.26PubMed Central. Effects of Opioids on Immune and Endocrine Function in Patients with Cancer Pain
The hormonal effects are better established. Long-term opioid use frequently suppresses the body’s production of sex hormones, a condition called opioid-induced hypogonadism. In men this can mean low testosterone, fatigue, reduced bone density, and sexual dysfunction. In women it can cause irregular or absent periods and similar quality-of-life problems. Opioid-induced endocrine disruption should be actively considered and screened for in anyone on long-term therapy, especially patients already dealing with cancer.26PubMed Central. Effects of Opioids on Immune and Endocrine Function in Patients with Cancer Pain
Opiates and Newborns
When a pregnant person takes opiates regularly, the fetus develops physical dependence in utero. After birth, the newborn goes through withdrawal, a condition called neonatal opioid withdrawal syndrome (NOWS). Because opioid receptors are concentrated in the central nervous system and the gastrointestinal tract, the signs in infants are predominantly neurological and digestive: tremors, high-pitched crying, poor feeding, loose stools, and difficulty sleeping.27Pediatrics. Neonatal Opioid Withdrawal Syndrome
The timing of withdrawal depends on the drug involved. Heroin withdrawal often begins within the first 24 hours, while methadone withdrawal typically starts between one and three days after birth and can sometimes be delayed up to a week, which means some infants are already discharged before symptoms appear.27Pediatrics. Neonatal Opioid Withdrawal Syndrome Subacute signs can linger for months. Treatment usually involves opioid replacement therapy for the infant, most commonly morphine or methadone, carefully tapered as the baby stabilizes. Clonidine has also shown benefit as an add-on when opioid treatment alone is not enough.28PubMed Central. Neonatal abstinence syndrome: essentials for the practitioner
Medication-Assisted Treatment for Opioid Use Disorder
Opioid use disorder is a chronic brain condition driven by the neuronal rewiring that comes from repeated opioid exposure. Tolerance, dependence, and addiction are all manifestations of these brain changes.29PubMed Central. The neurobiology of opioid dependence: implications for treatment Chronic use creates an altered baseline in the brain’s reward and stress circuits, so that normal functioning comes to require the drug.30PubMed Central. Neurobiology of opioid dependence in creating addiction vulnerability
The most effective treatments use medications that act on the same opioid receptors but in a more controlled and less harmful way. Methadone is a full opioid agonist given in supervised daily doses to prevent withdrawal and cravings without producing the intense highs of heroin or illicit fentanyl. Buprenorphine is a partial agonist, meaning it activates the mu receptor enough to stave off withdrawal but has a ceiling effect that limits euphoria and overdose risk. Naltrexone takes the opposite approach: it blocks the receptor entirely, so that any opioid taken on top of it produces no effect.
A systematic review of retention in these programs found that patients on naltrexone or buprenorphine stayed in treatment longer than those receiving a placebo, and methadone was associated with better retention than buprenorphine combined with naloxone.31PubMed Central. Retention in medication-assisted treatment for opiate dependence: A systematic review Retention matters because staying on treatment is strongly linked to lower rates of relapse, overdose, and death. The metabolic side-effect profile also differs between the medications: buprenorphine-treated patients showed lower rates of metabolic syndrome compared to their methadone-treated counterparts, a consideration for people who will be on treatment for years.32Scientific Reports. Metabolic and Addiction Indices in Patients on Opioid Agonist Medication-Assisted Treatment: A Comparison of Buprenorphine and Methadone Each medication has trade-offs in terms of convenience, side effects, and how tightly it needs to be supervised, so the choice is typically tailored to the individual patient’s circumstances and history.